GC Green Cross Medical Foundation Introduces Latest Blood Test Technology for Minimal Residual Disease in Multiple Myeloma

Designated as a Global Reference Center

GC Green Cross Medical Foundation announced on January 12 that it has signed an agreement with Sevya, a global leader in multiple myeloma diagnostics, to introduce 'M-inSight,' the latest blood test technology for minimal residual disease (MRD) in multiple myeloma (MM), and has been designated as a global reference center.

Officials from GC Green Cross Medical Foundation and Sevya are taking a commemorative photo after signing an agreement to introduce 'M-inSight,' the latest blood test technology for minimal residual disease (MRD) in multiple myeloma (MM). Photo by GC Green Cross Medical Foundation

M-inSight is an MRD test that detects trace amounts of cancer cells remaining in the body after treatment. It is characterized by overcoming the invasiveness and limitations of conventional bone marrow-based tests. Notably, the latest mass spectrometer has been introduced as a core device in this collaboration. This enables the precise detection of patient-specific proteins, allowing for early prediction of relapse risk and real-time assessment of treatment response.

Through this partnership, GC Green Cross Medical Foundation and Sevya have agreed to provide rapid and accurate MRD testing for multiple myeloma patients worldwide, and to contribute to the advancement of medical services and medicine through academic-industry collaborative research.

Going forward, GC Green Cross Medical Foundation will: ▲ serve as a global hub lab by utilizing its worldwide partner network in Asia, the Middle East, Europe, and beyond; ▲ secure state-of-the-art testing infrastructure based on advanced mass spectrometry equipment and a team of skilled experts; and ▲ expand joint research and information exchange with academic societies and research institutions both domestically and internationally.

During the selection process, GC Green Cross Medical Foundation competed in a year-long bidding process with other countries in Asia. The designation as a global reference center marks the third such center in the world, following the United States and France.

Lee Sangkon, President of GC Green Cross Medical Foundation, stated, "This collaboration with Sevya marks an important starting point for innovation in treatment strategy development and prognosis management for multiple myeloma patients, as it introduces Asia's first patient-friendly, blood-based MRD test. GC Green Cross Medical Foundation will continue to take the lead in promoting human health based on our global network and advanced testing capabilities."